Another study (36) showed that atovaquone, an antiprotozoal drug and MDSC inhibitor, reduced tumor growth in paclitaxel-resistant models of breast cancer (including TNBC), decreasing the production of TGFβ and IL-10 (immunosuppressive cytokines secreted by MDSCs), with a decrease in Tregs at the tumor site (36). This evidence concerns the gene IL10 and neoplasm.